Document is current
Any future updates will be listed below
-
Authors
Stubbs, Michelle A.
Clark, Vanessa L.
Gibson, Peter G.
Yorke, Janelle
McDonald, Vanessa M.
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (Seed Grant)
University of Newcastle Australia (Postgraduate Research Scholarship)
- License Information
-
More Information
Article History
Received: 27 February 2022
Accepted: 29 November 2022
First Online: 12 December 2022
Declarations
:
: Ethics approval was granted from Hunter New England Local Health District Human Research Ethics Committee (08/08/20/3.10). The study was conducted in accordance with Good Clinical Practice Guidelines and ethical principles consistent with the Declaration of Helsinki. All participants provided written informed consent, with investigators obtaining signed and dated consent forms.
: Not applicable.
: M.A. Stubbs reports personal speaker fees from AstraZeneca, outside the submitted work. V.L. Clark receives a fellowship from the National Health and Medical Research Council, Centre of Research Excellence in Severe Asthma, and also reports a grant from AstraZeneca to cover research-related costs, received for providing education to AstraZeneca staff, outside the submitted work. J. Yorke reports personal fees from Dysnpoae-12 questionnaire, personal fees from SGRQ-I questionnaire, outside the submitted work. P.G. Gibson reports personal fees from AstraZeneca, GlaxoSmithKline, Novartis, Grants from AstraZeneca, GlaxoSmithKline, outside the submitted work. V.M. McDonald reports grants and speaker fees from GlaxoSmithKline and AstraZeneca, and advisory board fees from Novartis, all outside the submitted work.
